



UNIVERSITY OF  
BIRMINGHAM

INSTITUTE OF  
CANCER AND  
GENOMIC SCIENCES

**Academic Department of Surgery**

Office 16, 2<sup>nd</sup> Floor,  
Institute of Translational Medicine,  
Heritage building  
University of Birmingham  
Birmingham, B15 2TH  
United Kingdom

16<sup>th</sup> December 2025

To Whom it may concern:

**Re: SurgWeek-2 study**

I am writing to confirm that 'SurgWeek-2' is an observational study that does not require any changes to be made to normal patient pathways. No additional patient follow-up is required for this study, and patients should have clinical follow-up as per normal practice at their hospital. The study is coordinated by the NIHR Global Health Research Unit on Global Surgery, a research unit of the University of Birmingham, a public research university in the United Kingdom. The study is a non-profit observational non-interventional international cohort study that is not aimed at developing any device/drug. No funds will be transferred to collaborators or participating hospitals.

Yours faithfully,

Dmitri Nepogodiev, MBChB

On behalf of the SurgWeek-2 Steering Group